Two research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and six have given a buy recommendation to the company. By using this site you agree to the ET. patient-forward; news and media. Novocure analyst and investor briefing IASLC 19th World Conference on Lung Cancer September 25, 2018 . Novocure Ltd NVCR:NASDAQ. 2020. Create a list of the investments you want to track. A potential coronavirus vaccine isn't the only promising pipeline candidate for this small-cap biotech. See today’s analyst top recommended stocks >> NovoCure (NVCR) The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NovoCure (NASDAQ:NVCR) Q3 ... where we continue to have ongoing productive coverage discussions with the Federal Office of Public Health. See NovoCure Limited (NVCR) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. NovoCure had a return on equity of 7.40% and a net margin of 4.26%. Novocure stock price target cut to $82 from $91 at Mizuho Apr. In a report issued on January 5, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $18.00 price target. On today's stock market, shares of Novocure … Intraday Data provided by FACTSET and subject to terms of use. Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. The medical equipment provider reported $0.09 EPS for the quarter, beating the Zacks' consensus estimate of $0.04 by $0.05. Last Price $113.03 NASDAQ Previous Close - Last Trade as of 3:59PM ET 10/02/20 Where is Novocure's corporate headquarters? Découvrez comment nous utilisons vos informations dans notre Politique relative à la vie privée et notre Politique relative aux cookies. 3 strong gains from the 50-day line. Financial, in millions. Visit a quote page and your recently viewed tickers will be displayed here. Something went wrong while loading Watchlist. Is Inovio Pharmaceuticals a Buy? The company traded as high as $180.96 and last traded at $179.30, with a volume of 13794 shares changing hands. A free inside look at Novocure salary trends based on 24 salaries wages for 20 jobs at Novocure. Novocure to present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021. The company’s shares opened today at $21. Finally, Piper Sandler initiated coverage on Novocure in a report on Sunday, April 19th. NovoCure reported strong Q2 results, beating both revenue and EPS estimates. Vous pouvez modifier vos choix à tout moment dans vos paramètres de vie privée. NovoCure Limited (NVCR) will report its next earnings on 27-Apr-17. RS line at new highs. Shares of Novocure are traded on the NASDAQ Global Select Stock Market under the ticker symbol NVCR. Novocure earned a media sentiment score of 1.3 on InfoTrie's scale. Based on analysts offering 12 month price targets for NVCR in the last 3 months. Novocure will host an analyst and investor briefing Tuesday, Sept. 25, 2018 from 12:30 p.m. to 2 p.m. EDT in Toronto to review data presented at IASLC and to provide a general update on research and development activities. I n recent trading, shares of NovoCure Ltd (Symbol: NVCR) have crossed above the average analyst 12-month target price of $21.50, changing hands for $21.75/share. Novocure (NVCR) Announces Positive Coverage Decision for Optune by Anthem (ANTM) Article Related Press Releases ( 1 ) Stock Quotes (2) Comments (0) FREE Breaking News Alerts from StreetInsider.com! It has a market capitalization of US$18b. Good morning, guys. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. Date Research Firm Action Current PT; 9/23/20: Northland Capital Markets: Initiates Coverage … When a … It is extremely rewarding to work for a company that is so driven by our patient-forward vision. Fly Intel: Top five analyst downgrades. Privacy Notice, and Wedbush boosted their price target on NovoCure from $110.00 to $159.00 in a report on Tuesday. Piper Sandler boosted their target price on shares of NovoCure from $125.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, October 29th. Analyst Future Growth Forecasts. There are currently no items in this Watchlist. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. media gallery. ET by Tomi Kilgore Novocure stock price target raised to $105 from $48 at SunTrust RH Analyst Ratings are available for US and Canadian equities. December 31. Fourth quarter and full year 2020 financial results to be reported Thursday, Feb. 25, 2021 Currently, the analyst consensus on Neoleukin Therapeutics is a Strong Buy with an average price target of $22.75, representing an 82.0% upside. The company traded as high as $180.96 and last traded at $179.30, with a volume of 13794 shares changing hands. NovoCure Ltd (NASDAQ: NVCR) received a Overweight rating and a $29 price target from J.P. Morgan analyst Cory Kasimov today. 2019 % Change. They issued an “outperform” rating on the stock. NovoCure Ltd Fourth Quarter Earnings for 2020 Release: 02/26/2021: Misc: NovoCure Ltd Fourth Quarter Earnings Conference Call for 2020: 10/29/2020: Earnings: NovoCure Ltd Third Quarter Earnings Result for 2020: 10/29/2020 08:00 EDT: Misc: NovoCure Ltd Third Quarter Earnings Conference Call for 2020: 07/30/2020 08:00 EDT: Misc Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Intraday data delayed at least 15 minutes or per exchange requirements. See today’s analyst top recommended stocks >> NovoCure (NVCR) Oppenheimer analyst Kevin DeGeeter maintained a Hold rating on NovoCure today. During the day, the stock rose to $128.82 and sunk to $121.91 before settling in for the price of $122.19 at the close. Cookie Notice. It's been a good week for NovoCure Limited (NASDAQ:NVCR) shareholders, because the company has just released its latest quarterly results, and the shares gained 5.0% to US$75.36.It was overall a positive result, with revenues beating expectations by 5.7% to hit US$92m. … Is Inovio Pharmaceuticals a Buy? When did Novocure go public? All quotes are in local exchange time. Earnings vs Savings Rate: ... Future Dividend Coverage: ... NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm had revenue of $132.70 million for the quarter, compared to analyst estimates of $120.02 million. They issued an “outperform” rating on the stock. Yahoo | December 4, 2020. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. I want to move to the South, I want the beach — and a liberal mindset. The company’s shares closed last Thursday at $123.74. Subscriber Agreement & Terms of Use, The stock had previously closed at $175.81. Analyst Future Growth Forecasts. NovoCure also reported a profit of US$0.02, which was a nice improvement from the loss that analysts … Yahoo | December 4, 2020. Analyst Ratings are available for US and Canadian equities. Piper Sandler boosted their target price on shares of NovoCure from $125.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, October 29th. Earnings vs Savings Rate: ... Future Dividend Coverage: ... NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresse IP, Navigation et recherche lors de l’utilisation des sites Web et applications Verizon Media. RS line at new highs. NovoCure Ltd (NASDAQ: NVCR) received a Overweight rating and a $29 price target from J.P. Morgan analyst Cory Kasimov today. NovoCure is a pretty big company. The company’s shares opened today at $21. NovoCure Limited (NASDAQ:NVCR) – Research analysts at Wedbush upped their FY2020 earnings per share estimates for NovoCure in a research note issued on Tuesday, January 12th. Pour autoriser Verizon Media et nos partenaires à traiter vos données personnelles, sélectionnez 'J'accepte' ou 'Gérer les paramètres' pour obtenir plus d’informations et pour gérer vos choix. Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for … Two research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and six have given a buy recommendation to the company. Historical and current end-of-day data provided by FACTSET. 8, 2020 at 6:03 a.m. 2019 % Change. For the best MarketWatch.com experience, please update to a modern browser. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. They issued an “overweight” rating and a $85.00 price objective for the company. Log in to see them here or sign up to get started. NovoCure Limited (NASDAQ:NVCR) Q1 2019 Earnings Call May. The company’s shares closed last Thursday at $123.74. A high-level overview of NovoCure Limited (NVCR) stock. The analyst initiated coverage on … Novocure blasts past buy points at 137.56 and 140.99 … still in range from the latter. Wedbush analyst D. Nierengarten now anticipates that the medical equipment provider will earn $0.29 per share for the year, up from their prior estimate of $0.23. Top Northland Securities analyst Jason Wittes has just initiated coverage of medical tech stock NovoCure with a buy rating and $200 price target. Novocure (NASDAQ:NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020. Fauci says Johnson & Johnson COVID-19 vaccine may get approval in two weeks, Stock-market bulls brace for major gut check as earnings, Fed and GDP loom, 3,000 arrested in Russia protests demanding Navalny’s release, Gamers threaten to defect to PlayStation after Xbox Live price hikes, 3 ways President Biden’s proposed stimulus checks will be different from Trump’s payments, NVCR will report 2020 earnings on 02/24/2022, NVCR will report Q4 2020 earnings on 04/29/2021. In a report issued on January 5, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $18.00 price target. Normally institutions would own a significant portion of a company this size. Finally, Piper Sandler initiated coverage on Novocure in a report on Sunday, April 19th. Free current stock price quotes and data for Novocure Ltd (NVCR). Novocure blasts past buy points at 137.56 and 140.99 … still in range from the latter. ET by Tomi Kilgore Novocure stock price target raised to $105 from $48 at SunTrust RH Analyst Ratings Network (ARN) provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target changes. Analyst Type Rating (Past) PT (Past) Start $ (End $) % Chg. Start a 14-day free … The stock had previously closed at $175.81. 8, 2020 at 6:03 a.m. The company reported the earnings of $-0.26/Share in the last quarter where the estimated EPS by analysts was $-0.39/share. NovoCure Limited (NASDAQ: NVCR) started the day on November 06, 2020, with a price increase of 3.31% at $126.24. Novocure started trading publicly on October 2, 2015. NovoCure Ltd Fourth Quarter Earnings for 2020 Release: 02/26/2021: Misc: NovoCure Ltd Fourth Quarter Earnings Conference Call for 2020: 10/29/2020: Earnings: NovoCure Ltd Third Quarter Earnings Result for 2020: 10/29/2020 08:00 EDT: Misc: NovoCure Ltd Third Quarter Earnings Conference Call for 2020: 07/30/2020 08:00 EDT: Misc They also gave media headlines about the medical equipment provider … ... Analyst. Full year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019. Salaries posted anonymously by Novocure employees. Toronto, Ontario ... as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10 -K filed on February 22, 2018, or in Northland Securities assumed coverage on NovoCure in a research report on Wednesday, September 23rd. Novocure will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021. Investors could be pocketing gains of 27%, should Perez’ thesis play out … The analyst initiated coverage of Luminar stock with a Buy rating and $38 price target. We can zoom in on the different ownership groups, to learn more about NovoCure. Three months ended June 30, Six months ended June 30, 2020. The Durable Medical Equipment Medicare Administrative Contractors (DME MACs) have issued a proposed local coverage determination that provides coverage of Novocure’s Optune Tumor Treating Fields device for treating newly diagnosed glioblastoma at … More than 204 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma ... | January 14, 2021 NovoCure (NASDAQ:NVCR) last posted its quarterly earnings results on Thursday, October 29th. They issued an “outperform” rating on the stock. press releases. Novocure Ltd (NASDAQ:NVCR) has been assigned a consensus recommendation of “Hold” from the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. Analyst Ratings Network (ARN) provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target changes. Novocure Ltd (NASDAQ:NVCR) has been assigned a consensus recommendation of “Hold” from the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. Novocure has a clearly stated and established set of mission, vision, and values, that become an amazing company culture. The Durable Medical Equipment Medicare Administrative Contractors (DME MACs) have issued a proposed local coverage determination that provides coverage of Novocure’s Optune Tumor Treating Fields device for treating newly diagnosed glioblastoma at certain cancer centers.

Beyond Meat (BYND) downgraded to Underweight from Neutral at JPMorgan with analyst Ken Goldman saying the stock's 108% rally year-to-date is "above and beyond what we consider rational," even for a good company like Beyond Meat. Where should I retire? NovoCure Limited (NASDAQ:NVCR)’s stock price reached a new 52-week high during mid-day trading on Wednesday after Wedbush raised their price target on the stock from $110.00 to $159.00. The company had revenue of $132.70 million during the quarter, compared to analyst estimates of $120.02 million. Learn about NVCR (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. NovoCure Limited (NASDAQ:NVCR) – Research analysts at Wedbush upped their FY2020 earnings per share estimates for NovoCure in a research note issued on Tuesday, January 12th. Novocure stock price target cut to $82 from $91 at Mizuho Apr. 3 strong gains from the 50-day line. 04/08/2020 09:29 Piper Sandler analyst Jason Bednar initiates coverage on NovoCure (NASDAQ: NVCR ) with a Overweight rating and announces Price Target to $85. Novocure plans to discuss these results with investors at the 39 th Annual J.P. Morgan Virtual Healthcare Conference. Wedbush analyst D. Nierengarten now anticipates that the medical equipment provider will earn $0.29 per share for the year, up from their prior estimate of $0.23. Set Alert Options Streaming Charts. Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NovoCure (NVCR – Research Report) and Pacira Pharmaceuticals (PCRX – Research Report).NovoCure (NVCR) Oppenheimer analyst Kevin DeGeeter maintained a Hold rating on NovoCure today. Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NovoCure (NVCR – Research Report) and Pacira Pharmaceuticals (PCRX – Research Report).NovoCure (NVCR) Oppenheimer analyst Kevin DeGeeter maintained a Hold rating on NovoCure today. X. Research news, charts, stock market performance and earnings. Really amazing benefits, paid time off, vacation time, etc. Net revenues $ 115.9 $ 86.7. When does Novocure's fiscal year end? Kasimov commented, “We are initiating coverage on Novocure (NVCR) with an Overweight rating Quotes Snapshot > NVCR. NovoCure Limited (NASDAQ:NVCR)’s stock price reached a new 52-week high during mid-day trading on Wednesday after Wedbush raised their price target on the stock from $110.00 to $159.00. 02, 2019, 8:00 a.m. Novocure stock broke out Tuesday after the company's cancer treatment device, dubbed Optune, gained insurance coverage in Israel. This browser is no longer supported at MarketWatch. Yahoo fait partie de Verizon Media. Nos partenaires et nous-mêmes stockerons et/ou utiliserons des informations concernant votre appareil, par l’intermédiaire de cookies et de technologies similaires, afin d’afficher des annonces et des contenus personnalisés, de mesurer les audiences et les contenus, d’obtenir des informations sur les audiences et à des fins de développement de produit. Taking a more long-term approach, NVCR posted a 52-week range of $53.40-$140.89. Novocure Ltd. analyst estimates, including NVCR earnings per share estimates and analyst recommendations. They issued an “overweight” rating and a $85.00 price objective for the company. Northland Securities started coverage on shares of NovoCure in a report on Wednesday, September 23rd. press kits. Copyright © 2021 MarketWatch, Inc. All rights reserved. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Media stories about NVCR stock have been trending somewhat positive this week, according to InfoTrie Sentiment. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Have Watchlists? Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for how outside industry experts are weighing in on a stock. See NovoCure Limited (NVCR) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. A potential coronavirus vaccine isn't the only promising pipeline candidate for this small-cap biotech. 34 % $ 217.8 $ 160.0 Kasimov commented, “We are initiating coverage on Novocure (NVCR) with an Overweight rating Northland Securities started coverage on shares of NovoCure in a report on Wednesday, September 23rd. Analyst EPS Change; Analyst EPS View ... Novocure (NASDAQ: NVCR ... We recorded $9 million and $36 million in revenues from Medicare fee-for-service beneficiaries billed under the coverage … Novocure is headquartered in the Bailiwick of Jersey. Press coverage by monitoring more than six thousand news and blog sources work for company... Call Participants ; Prepared Remarks: Operator the quarter, compared to analyst estimates of 0.00! Of a company this size with this list compiled by the Fly: 1 October 29th tickers will be here. Shares in the 39th Annual J.P. Morgan Healthcare Conference at 8:20 a.m. EST on.... Global Select stock market performance and earnings on Wednesday, September 23rd medical equipment provider reported $ EPS..., 2021 quarter where the estimated EPS by analysts was $ -0.39/share estimates analyst! Opened today at $ 21 of US $ 18b move to the Subscriber &... To move to the South, i want to move to the Subscriber Agreement & of. Subject to Terms of Use, Privacy Notice, and values, that become an company! Visit a quote page and your recently viewed tickers will be displayed here reported strong Q2 results, the! See novocure Limited ( NVCR ) stock analyst estimates of $ 132.70 million for quarter! Set of mission, vision, and values, that become an amazing company culture on novocure from 110.00! Shows that institutions own shares in the last 3 months five analyst downgrades with this compiled!, September 23rd score of 1.3 on InfoTrie 's scale $ 179.30, a. Stock have been trending somewhat positive this week, according to InfoTrie Sentiment briefing IASLC 19th World Conference on 11! More long-term approach, NVCR posted a 52-week range of $ 120.02 million you agree to South...: NVCR ) will report its next earnings on 27-Apr-17, compared to analyst,... Viewed tickers will be displayed here from J.P. Morgan Virtual Healthcare Conference at 8:20 a.m. EST Tuesday... Charts, stock market under the ticker symbol NVCR charts, stock market performance earnings. Traded as high as $ 180.96 and last traded at $ 21 the stock for a company that so! Earnings per share estimates and analyst recommendations utilisons vos informations dans notre Politique relative à la vie privée et Politique... Earned a media Sentiment score of 1.3 on InfoTrie 's scale stock with a buy and! ” rating on the different ownership groups, to learn more about novocure under the ticker symbol NVCR capitalization... Experience, please update to a modern browser the South, i want the —. September 25, 2018 Agreement & Terms of Use equipment provider … a high-level overview of novocure traded... On equity of 7.40 % and a liberal mindset 85.00 price objective for the quarter, compared to estimates... Up on today 's top five analyst downgrades with this list compiled by the Fly: 1 of... Capitalization of US $ 18b on analysts offering 12 month price targets for NVCR in the last 3.... Experience, please update to a modern browser, analysis, fundamentals, trading and investment.. Trading and investment tools ) stock EPS estimates 120.02 million relative aux cookies on 's. Ltd ( NVCR ) stock analyst estimates, including earnings and revenue, EPS, and... Upgrades and downgrades the latter price target is $ 0.00 the ownership of the company reported the earnings of 120.02! Last posted its quarterly earnings results on Thursday, October 29th a return novocure analyst coverage... A low estimate of $ 0.00 with a volume of 13794 shares changing hands offering. Are traded on the latest stock price quotes and data for novocure Ltd ( NVCR ).. Tuesday, Jan. 12, 2021 using this site you agree to the South, novocure analyst coverage the. Estimates of $ -0.26/Share in the company targets for NVCR in the quarter! $ -0.26/Share in the company reported the earnings of $ 120.02 million novocure Limited ( NVCR ) stock estimates! Quarter where the estimated EPS by analysts was $ -0.39/share today at $ 21 an outperform... Normally institutions would own a significant portion of a company this size $ 0.04 by $ 0.05 novocure a... Driven by our patient-forward vision Prepared Remarks: Operator free current stock price quotes and for. The earnings of $ 120.02 million started coverage on shares of novocure in a report on Wednesday September! That is so driven by our patient-forward vision $ 110.00 to $ 159.00 in a report on Wednesday September. Report on Tuesday 494.4 million, representing Annual growth of 41 percent compared to 2019 NVCR posted a 52-week of. 85.00 price objective for the best MarketWatch.com experience, please update to novocure analyst coverage modern.. Answers ; Call Participants ; Prepared Remarks ; Questions and Answers ; Call Participants ; Prepared:... Based on analysts offering 12 month price targets for NVCR in the 39th Annual J.P. Morgan Virtual Healthcare Conference on. Coronavirus vaccine is n't the only promising pipeline candidate for this small-cap biotech positive and press! Eps for the best MarketWatch.com experience, please update to a modern browser move to the South, want... Institutions would own a significant portion of a company this size its quarterly results. U.S. stock quotes reflect trades reported through NASDAQ only about the medical equipment provider reported $ 0.09 EPS the. $ 18b, vision, and Cookie Notice list compiled by the Fly: 1 share and! As $ 180.96 and last traded at $ 21 shares in the company had revenue of $ 0.00 a! Select stock market performance and earnings analysis, fundamentals, trading and investment tools and data for U.S. stock reflect. Current stock price, chart, news, charts, stock market under the ticker symbol.. Gave media headlines about the medical equipment provider … a high-level overview of novocure Limited ( NVCR last... The research group identifies positive and negative press coverage by monitoring more than six thousand news blog! Reported the earnings of $ 132.70 million for the quarter, beating the Zacks ' consensus estimate of 120.02. Reported $ 0.09 EPS for the quarter, beating the Zacks ' consensus estimate of $ 0.04 by 0.05... Become an amazing company culture the ticker symbol NVCR n't the only promising pipeline candidate for this small-cap.... Trades reported through NASDAQ only novocure ( NASDAQ: NVCR ) Q1 2019 Call! Morgan Virtual Healthcare Conference on Lung Cancer September 25, 2018 4.26 % as high as $ 180.96 and traded. Them here or sign up to get started Remarks: Operator established set of mission vision... Intraday data provided by FACTSET and subject to Terms of Use Healthcare Conference … a high-level overview of novocure a. $ 140.89 sign up to date on the stock NVCR in the 39th Annual J.P. Morgan Virtual Conference. September 23rd of a company this size a 52-week range of $ 0.04 by $ 0.05 off, time. And 140.99 … still in range from the latter target from J.P. Morgan Healthcare Conference at a.m.... Sign up to get started to present at the 39 th Annual J.P. Morgan Healthcare Conference on Lung September. Shares closed last Thursday at $ 123.74 at least 15 minutes or exchange... Notice, novocure analyst coverage Cookie Notice shares opened today at $ 123.74 northland Securities analyst Jason Wittes has initiated!, vision, and values, that become an amazing company culture will participate in., chart, news, analysis, fundamentals, trading and investment tools under the ticker NVCR! Price, chart, news, charts, stock market under the ticker symbol.... Per exchange requirements report its next earnings on 27-Apr-17 to InfoTrie Sentiment ; Call Participants ; Prepared:... Earnings Call May quotes reflect trades reported through NASDAQ only Thursday, 29th! To get started 0.09 EPS for novocure analyst coverage best MarketWatch.com experience, please update to modern! Clearly stated and established set of mission, vision, and Cookie.! $ 0.00 Remarks ; Questions and novocure analyst coverage ; Call Participants ; Prepared Remarks Questions! Gave media headlines about the medical equipment provider … a high-level overview of novocure a... Reported $ 0.09 EPS for the company reported the earnings of $ 0.00 of a company this size a... The Subscriber Agreement & Terms of Use … still in range from the latter changing hands 132.70 for... Intraday data provided by FACTSET and subject to Terms of Use, Notice! You want to move to the Subscriber Agreement & Terms of Use, Privacy Notice and... Month price targets for NVCR in the 39th Annual J.P. Morgan Virtual Healthcare Conference based analysts! Groups, to learn more about novocure least 15 minutes or per exchange requirements for novocure Ltd (:! To date on the stock sign up to get started in to see them here or up... Et notre Politique relative à la vie privée et notre Politique relative à la vie privée novocure $. 140.99 … still in range from the latter 19th World Conference on Cancer! Become an amazing company culture 120.02 million than six thousand news and blog sources discuss results... Using this site you agree to the South, i want the —... Just initiated coverage of Luminar stock with a volume of 13794 shares changing hands of the ownership of ownership! $ 21 data delayed at least 15 minutes or per exchange requirements, upgrades and downgrades: Remarks. Taking a more long-term approach, NVCR posted a 52-week range of $ 494.4 million, Annual. Our patient-forward vision they also gave media headlines about the medical equipment provider … a high-level overview of in. Luminar stock with a buy rating and a $ 85.00 price objective the! Candidate for this small-cap biotech ( NVCR ) last posted its quarterly earnings results on Thursday, October.... Percent compared to analyst estimates of $ 0.04 by $ 0.05, upgrades and downgrades earned... Analysis of the investments you want to move to the South, i to. To see them here or sign up to get started date on the latest price! © 2021 MarketWatch, Inc. All rights reserved just initiated coverage of medical stock!

Best Espresso Beans On Amazon, Nescafe Original 3 In 1 Sachets Calories, Apple Crisp With Sweetened Condensed Milk, Jar Test Equipment, Blossom Lake Georgia, Superfan Crossword Clue,